JPRN-UMIN000018296已完成未知
Impact of raloxifene, eldecalcitol and their combination therapy on bone indices in postmenopausal subjects with osteoporosis and chronic kidney disease stage 3: Re Bone Study - Impact of raloxifene, eldecalcitol and their combination therapy on bone indices in postmenopausal subjects with osteoporosis and chronic kidney disease stage 3: Re Bone Study
Osaka City University Graduate School of Medicine0 个研究点目标入组 0 人开始时间: 2015年7月13日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
study terminated
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1)Patients treated with Bisphosphonates within 48 weeks of the enrollment. (2)Patients who have been treated with parathyroid hormone, anti-RANKL antibody or Kathepsin K inhibitors. (3)Patients who have been treated with medication which may affect to the bone metabolism as follows within 8 weeks of the enrollment, except calcium preparations, (a)Active vitamin D including external drugs (b)Selective Estrogen Receptor Modulators (SERM) (c)Calcitonin preparations (d)Vitamin K2 preparations (e)Ipriflavone preparations (f)Sex hormones except virginal tablet or virginal balm (g)Steroid preparations except inhaler, nasal drip, external drugs or local injection. (h) Warfarin (i)Other drugs which affect to the bone metabolism (4)Patients who have Diabetes Mellitus (5)Patients treated with other test drugs (including placebo) within 16 weeks of the enrollment. (6)Patients who have findings that may affect to the evaluation of bone mineral density in lumbar vertebra or hip, as follows (a)Patients who have bone fracture or severe deformity in L2-4 or hip (b)Patients who have degenerations or severe osteosclerosis in L2-4 or hip (c)Patients who have severe extra-vertebral calcifications in L2-4 (d)Patients who have other abnormal findings that may affect to the evaluation of bone mineral density in lumbar vertebra (7)Patients who have history of deep vein thrombosis, pulmonary thromboembolism or occlusion of retinal vein (8)Patients whose total serum calcium corrected for albumin levels are over +0.5mg/dL of upper limit or whose Ca/Crelevels are over 0.3 (9)Patients who have history of ureteral stones (10)Patients who have cancer (11)Patients who have severe liver dysfunction (12)Patients who have severe heart dysfunction (13)Patients who have drug hypersensitivity to SERM or Vitamin D preparations (14)Patients judged as unsuitable for the study by the investigator for other reasons
研究者
相似试验
招募中
不适用
Effect of Eldcalcitol/ Raloxifene combination therapy for fall prevention in primary osteoporosis patients: a randomized controlled study.osteoporosisJPRN-UMIN000008216igata Rehabilitation Hospital100
招募中
不适用
Effects of Eldecalcitol and Raloxifene on the suppression of new vertebral fracture with osteoporosis in perimenopausal women or ovariectomy patients: Randomized controlled trialosteoporosis in perimenopausal women or ovariectomy patientsJPRN-UMIN000009378Tokyo Women's Medical University Hospital360
招募中
不适用
Effects of Eldecalcitol and/or Raloxifene on insulin sensitivity and carotid intima-media thickness in postmenopausal woman.Postmenopausal osteoporosisJPRN-UMIN000012269Kyushu-University Hospital60
已完成
3 期
Raloxifene Use for The HeartCardiovascular DiseasesBreast NeoplasmsNCT00190593Eli Lilly and Company10,000
已完成
3 期
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With OsteoporosisOsteoporosis, PostmenopausalNCT00670319Eli Lilly and Company7,705